PP_1170x120_10-25-21

COVID-19 trials

Glenmark to commence new phase 3 clinical trial for COVID-19 in India

Glenmark to commence new phase 3 clinical trial for COVID-19 in India

MUMBAI, India — Glenmark Pharmaceuticals announced a new randomized, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy. Favipiravir is an oral antiviral drug approved in Japan since 2014. It has a unique mechanism of action by which it inhibits viral replication: Umifenovir is another oral